Pemanfaatan CRISPR dalam Pengembangan Vaksin Generasi Baru terhadap Virus Tropis
DOI:
https://doi.org/10.59031/jnts.v3i2.793Keywords:
CRISPR, Dengue, Gene Editing, Vaccine Design, Zika VirusAbstract
The development of vaccines for tropical viruses such as dengue and Zika presents a significant challenge in global health. These viruses not only cause serious health complications but also impact health systems and economies in tropical countries. CRISPR/Cas9 technology offers an innovative solution to accelerate vaccine development by enabling precise gene editing. This study aims to explore the potential of CRISPR in accelerating the design and production of vaccines for tropical viruses. The method used in this study is a laboratory-based experimental design involving genetic engineering, with dengue and Zika virus genome models. The first step involves identifying virus target genes using the CRISPR/Cas9 system, which allows the detection of specific genes involved in pathogenesis and immune responses. Subsequently, genetic constructs are designed to generate vaccine candidates that can efficiently and precisely target pathogens. The resulting vaccines are tested in vitro in cell cultures to observe immune responses and their effectiveness against virus infections. The results show that CRISPR not only accelerates the process of identifying and engineering vaccine genes but also significantly improves vaccine production efficiency. CRISPR-based vaccines demonstrate higher immunogenicity compared to conventional methods, thus holding potential as the foundation for developing faster and safer next-generation vaccines. However, this study also identifies challenges related to off-target effects and the efficient delivery of CRISPR components, which require further research to ensure safety and efficacy in human clinical applications.
References
Abbas, S., Saeed, A., Bibi, M., Perveen, S., Masood, N. (2025). CRISPR-Cas: From bacterial immunity to precision genome engineering. Gene Reports, 40, Article 102296. https://doi.org/10.1016/j.genrep.2025.102296
Alghamdi, A. (2025). Next-generation vaccines: Tailoring immune responses for enhanced protection against emerging pathogens. Journal of Medicinal and Pharmaceutical Chemistry Research, 7(6), 1230–1247. https://doi.org/10.48309/jmpcr.2025.467445.1331
Azimzadeh, M., Mousazadeh, M., Jahangiri-Manesh, A., Khashayar, P., & Khashayar, P. (2022). CRISPR-powered microfluidics in diagnostics: A review of main applications. Chemosensors, 10(1), Article 3. https://doi.org/10.3390/chemosensors10010003
Bezbaruah, R., Chavda, V. P., Nongrang, L., Alom, S., Deka, K., Kalita, T., Ali, F., Bhattacharjee, B., & Vora, L. (2022). Nanoparticle-based delivery systems for vaccines. Vaccines, 10(11), Article 1946. https://doi.org/10.3390/vaccines10111946
Bhujbal, S., Bhujbal, R., & Giram, P. (2022). An overview: CRISPR/Cas-based gene editing for viral vaccine development. Expert Review of Vaccines, 21(11), 1581–1593. https://doi.org/10.1080/14760584.2022.2112952
Bhushan, K. (2020). Evolution and molecular mechanism of CRISPR/Cas9 systems. In Genome Engineering via CRISPR-Cas9 System (pp. 15–25). https://doi.org/10.1016/B978-0-12-818140-9.00002-7
Dara, M., Shafieipour, N., Saffar, M., Dianatpour, M., Tabei, S.-M.-B., & Dastgheib, S.-A. (2025). Diagnosis of infectious diseases by CRISPR/Cas system. OBM Genetics, 9(2). https://doi.org/10.21926/obm.genet.2502289
De La Fuente-Núñez, C., & Lu, T. K. (2017). CRISPR-Cas9 technology: Applications in genome engineering, development of sequence-specific antimicrobials, and future prospects. Integrative Biology (United Kingdom), 9(2), 109–122. https://doi.org/10.1039/c6ib00140h
de Oliveira Diniz, M., & de Souza Ferreira, L. C. (2010). Biotecnologia aplicada ao desenvolvimento de vacinas. Estudos Avancados, 24(70), 19–30. https://doi.org/10.1590/S0103-40142010000300003
Eslami, M., Fadaee Dowlat, B., Yaghmayee, S., Habibian, A., Keshavarzi, S., Oksenych, V., & Naderian, R. (2025). Next-generation vaccine platforms: Integrating synthetic biology, nanotechnology, and systems immunology for improved immunogenicity. Vaccines, 13(6), Article 588. https://doi.org/10.3390/vaccines13060588
Ganger, S., Harale, G., & Majumdar, P. (2023). Clustered regularly interspaced short palindromic repeats/CRISPR-associated (CRISPR/Cas) systems: Discovery, structure, classification, and general mechanism. In CRISPR/Cas-Mediated Genome Editing in Plants (pp. 65–98). https://www.scopus.com/inward/record.uri?eid=2-s2.0-85162140362&partnerID=40&md5=ff06ce430f88eb38446cb5925c0a6cad
Grobler, L., Suleman, E., & Thimiri Govinda Raj, D. B. (2021). Patents and technology transfer in CRISPR technology. In Progress in Molecular Biology and Translational Science, 180 (pp. 153–182). https://doi.org/10.1016/bs.pmbts.2021.01.009
Gupta, A., Rudra, A., Reed, K., Langer, R., & Anderson, D. G. (2024). Advanced technologies for the development of infectious disease vaccines. Nature Reviews Drug Discovery, 23(12), 914–938. https://doi.org/10.1038/s41573-024-01041-z
Hong, T., & Luo, Q. (2023). Advances in the RNA-targeting CRISPR-Cas systems [靶向RNA的CRISPR-Cas系统研究进展]. Shengwu Gongcheng Xuebao/Chinese Journal of Biotechnology, 39(4), 1363–1373. https://doi.org/10.13345/j.cjb.220633
Kistner, O. (2020). Vaccines: From development to market [Impfstoffe: Von der entwicklung zur marktreife]. Padiatrische Praxis, 92(3), 472–483. https://www.scopus.com/inward/record.uri?eid=2-s2.0-85091573772&partnerID=40&md5=6b6c977f9a131d4e9e6188dd514784ab
Kumar, A., Yau, Y.-Y., & Kumar, V. R. (2024). CRISPR-Cas: A history of discovery and innovation. In Gene Editing in Plants: CRISPR-Cas and Its Applications (pp. 1–15). https://doi.org/10.1007/978-981-99-8529-6_1
Kumar, M., Maiti, S., & Chakraborty, D. (2022). Capturing nucleic acid variants with precision using CRISPR diagnostics. Biosensors and Bioelectronics, 217, Article 114712. https://doi.org/10.1016/j.bios.2022.114712
Liang, X., Sun, L., Yu, T., Pan, Y., Wang, D., Hu, X., Fu, Z., He, Q., & Cao, G. (2016). A CRISPR/Cas9 and Cre/Lox system-based express vaccine development strategy against re-emerging Pseudorabies virus. Scientific Reports, 6, Article 19176. https://doi.org/10.1038/srep19176
Lu, B., Lim, J. M., Yu, B., Song, S., Neeli, P., Sobhani, N., K, P., Bonam, S. R., Kurapati, R., Zheng, J., & Chai, D. (2024). The next-generation DNA vaccine platforms and delivery systems: Advances, challenges and prospects. Frontiers in Immunology, 15, Article 1332939. https://doi.org/10.3389/fimmu.2024.1332939
Malla, A., Shanmugaraj, B., & Ramalingam, S. (2020). Emerging mosquito-borne arboviral infection Zika—An epidemiological review. Asian Pacific Journal of Tropical Biomedicine, 10(5), 193–200. https://doi.org/10.4103/2221-1691.281139
Masi, A., Antonacci, A., Moccia, M., Frisulli, V., De Felice, M., De Falco, M., & Scognamiglio, V. (2023). CRISPR-Cas assisted diagnostics: A broad application biosensing approach. TrAC - Trends in Analytical Chemistry, 162, Article 117028. https://doi.org/10.1016/j.trac.2023.117028
Mayran, C., Henry, S., Pinchon, E., Fournier-Wirth, C., Cantaloube, J. F., & Foulongne, V. (2022). CRISPR-Cas: The bacterial immunity that supports diagnostic in virology [CRISPR-Cas : l'immunité bactérienne au service du diagnostic virologique]. Virologie, 26(4), 303–313. https://doi.org/10.1684/vir.2022.0966
Messina, J. P., Kraemer, M. U. G., Brady, O. J., Pigott, D. M., Shearer, F. M., Weiss, D. J., Golding, N., Ruktanonchai, C. W., Gething, P. W., Cohn, E., Brownstein, J. S., Khan, K., Tatem, A. J., Jaenisch, T., Murray, C. J. L., Marinho, F., Scott, T. W., & Hay, S. I. (2016). Mapping global environmental suitability for Zika virus. eLife, 5, Article e15272. https://doi.org/10.7554/eLife.15272
Minet, C., Thévenon, S., Chantal, I., Solano, P., & Berthier, D. (2018). Mini-review on CRISPR-Cas9 and its potential applications to help controlling neglected tropical diseases caused by Trypanosomatidae. Infection, Genetics and Evolution, 63, 326–331. https://doi.org/10.1016/j.meegid.2018.02.030
Mohanty, B., Ahmad Mir, R., Priyadarshini, A., Ahmad Bhat, K., Barati, S., Roshani Asl, E., Choi, J. R., & Rasmi, Y. (2024). Potential use of CRISPR/Cas13 system for vaccine development against various RNA-viral infections. Future Virology, 19(10-11), 401–418. https://doi.org/10.1080/17460794.2024.2403253
Morgan, J., Strode, C., & Salcedo-Sora, J. E. (2021). Climatic and socio-economic factors supporting the co-circulation of dengue, Zika, and chikungunya in three different ecosystems in Colombia. PLoS Neglected Tropical Diseases, 15(3), Article e0009259. https://doi.org/10.1371/journal.pntd.0009259
Naeem, M., Alkhodairy, H. F., Ashraf, I., & Khalil, A. B. (2023). CRISPR/Cas system toward the development of next-generation recombinant vaccines: Current scenario and future prospects. Arabian Journal for Science and Engineering, 48(1), 1–11. https://doi.org/10.1007/s13369-022-07266-7
Nouri, F., Alibabaei, F., Forouzanmehr, B., Tahmasebi, H., Oksenych, V., & Eslami, M. (2025). Progress in CRISPR technology for antiviral treatments: Genome editing as a potential cure for chronic viral infections. Microbiology Research, 16(5), Article 104. https://doi.org/10.3390/microbiolres16050104
Pereira, C. A. D. M., Mendes, R. P. G., Silva, P. G. D., Chaves, E. J. F., & Pena, L. J. (2025). Vaccines against urban epidemic arboviruses: The state of the art. Viruses, 17(3), Article 382. https://doi.org/10.3390/v17030382
Rauf, M. A., Rao, A., Sivasoorian, S. S., & Iyer, A. K. (2025). Nanotechnology-based delivery of CRISPR/Cas9 for cancer treatment: A comprehensive review. Cells, 14(15), Article 1136. https://doi.org/10.3390/cells14151136
Razavi, Z., Soltani, M., Pazoki-Toroudi, H., & Chen, P. (2024). CRISPR-microfluidics nexus: Advancing biomedical applications for understanding and detection. Sensors and Actuators A: Physical, 376, Article 115625. https://doi.org/10.1016/j.sna.2024.115625
Sparrow, E., Hasso-Agopsowicz, M., Kaslow, D. C., Singh, K., Rao, R., Chibi, M., Makubalo, L. E., Reeder, J. C., Kang, G., Karron, R. A., Cravioto, A., Lanata, C. F., Friede, M., Abela-Ridder, B., Solomon, A. W., Dagne, D. A., & Giersing, B. (2022). Leveraging mRNA platform technology to accelerate development of vaccines for some emerging and neglected tropical diseases through local vaccine production. Frontiers in Tropical Diseases, 3, Article 844039. https://doi.org/10.3389/fitd.2022.844039
Wollert, D. (2020). Wet & dry lab activities to introduce students to CRISPR-based gene editing. American Biology Teacher, 82(5), 315–322. https://doi.org/10.1525/abt.2020.82.5.315
Yang, K. (2025). Accelerating vaccine development: Plug-and-play platforms for emerging infectious diseases. Virus Research, 358, Article 199601. https://doi.org/10.1016/j.virusres.2025.199601
Yang, P., Zeng, J., Li, L., Ma, R., Peng, J., Zhou, W., Fu, W., Wu, Y., & Zhang, Y. (2025). From Cas proteins to cutting-edge biosensors: A new era in clinical pathogen diagnostics. Journal of Infection, 91(1), Article 106526. https://doi.org/10.1016/j.jinf.2025.106526
Zakrzewska, M., & Burmistrz, M. (2023). Mechanisms regulating the CRISPR-Cas systems. Frontiers in Microbiology, 14, Article 1060337. https://doi.org/10.3389/fmicb.2023.1060337
Zhu, J., Ananthaswamy, N., Jain, S., Batra, H., Tang, W.-C., & Rao, V. B. (2022). CRISPR engineering of bacteriophage T4 to design vaccines against SARS-CoV-2 and emerging pathogens. In Methods in Molecular Biology, 2410 (pp. 209–228). https://doi.org/10.1007/978-1-0716-1884-4_10
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Journal of New Trends in Sciences
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
